Topics in Anti-Cancer Research: Volume 10
Description
Topics in Anti-Cancer Research covers new developments in the field of cancer diagnosis and drug therapy. Novel drugs as anticancer agents include natural and synthetic phenazirines and other anti-cancer compounds. The series also covers information on the current understanding of the pathology and molecular biology of specific neoplasms.
The diversity of research topics published in this book series give broad and valuable perspectives for cancer researchers, clinicians, cancer professionals aiming to develop novel anti-cancer targets and patents for the treatment of various cancers.
The topics covered in this volume are:
- Peptides can play a major role in combating cancer diseases
- Studying of the CLL after treatment using fractal parameter of neoplastic lymphocytes detection (¿NLD)
- Mechanistic insight of rhenium-based compounds as anti- cancer agents
- Targeting cancer-specific inflammatory components in cancer therapeutics
- Marine natural products as a source of novel anticancer agents: a treasure from the ocean
- PDX clinical trial design in anti-cancer research
All prices
More details
Content
- Cover
- Title
- Copyright
- End User License Agreement
- Contents
- Preface
- List of Contributors
- Peptides Can Play a Major Role in Combating Cancer Diseases
- Mohammad Hassan Houshdar Tehrani1,*
- INTRODUCTION
- Cancer Cells versus Normal Cells
- Cell Membrane and Non-Membrane Involved Anti-Cancer Mechanisms of Peptides
- Cell Membrane Involved Mechanism of Anticancer Peptides
- Non-Membrane Involved Mechanisms of Anticancer Peptides
- Anticancer Peptides Categories
- Antimicrobial Peptides
- Anti-inflammatory Peptides
- Antioxidant Peptides
- Peptide Conjugates
- Peptides as Targeting Probes (Homing Peptides) for Cancer Detection
- Summary
- CONCLUDING REMARKS
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEDGEMENTS
- REFERENCES
- Studying of the CLL After Treatment Using Fractal Parameter of Neoplastic Lymphocytes Detection (?nld)
- Mohammad Reza Rezaei1,* and Zahra Rostami2
- INTRODUCTION
- Leukemia Types
- Diagnosis
- Blood Tests for Diagnosis
- Image Processing for Diagnoses
- Image Acquisition
- Image Segmentation
- Nucleus Segmentation
- Features
- Classification
- Treatment
- METHODS AND MATERIALS
- The Fractal Dimension of Blood Lymphocytes
- RESULT
- Fractal Parameters of Neoplastic Lymphocytes Detection (?nld)
- CONCLUSION
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEDGEMENTS
- REFERENCES
- Mechanistic Insight of Rhenium-Based Compounds as Anti-Cancer Agents
- A. Harikrishnan1,*, Supreetha B.S.2 and Veena V.2,*
- INTRODUCTION
- RHENIUM BASED DRUGS IN CANCER IMAGING AND CANCER THERAPY
- MOLECULAR INSIGHTS OF ANTICANCER POTENTIAL OF RHENIUM-BASED COMPOUNDS
- CONCLUDING REMARKS
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEGEMENTS
- REFERENCE
- Targeting Cancer-Specific Inflammatory Components In Cancer Therapeutics
- V. Veena1,*, Pravallika Mandlipalli1 and A Harikrishnan2,*
- INTRODUCTION
- HISTORICAL PROSPECTIVE OF CANCER TREATMENT
- MOLECULAR BASIS OF CANCER AND MECHANISM OF CANCER RESISTANCE
- Deregulation of NF-?B Pathway
- Classical/Canonical Pathway
- Alternative/non-canonical Pathway
- Deregulation of PI3K/Akt Pathway
- CANCER RELATED INFLAMMATION (CRI)
- DECIPHERING THE MOLECULAR TARGETS OF CRI FOR TARGETED CANCER THERAPY
- CONCLUDING REMARKS
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEDGEMENTS
- REFERENCES
- Marine Natural Products as a Source of Novel Anticancer Agents: A Treasure from the Ocean
- Deepa S. Mandlik1,* and Satish K. Mandlik1
- INTRODUCTION
- MARINE-DERIVED NATURAL PRODUCTS AND THEIR CLASSIFICATION
- MARINE NATURAL PRODUCTS AS AN ANTICANCER AGENT
- Marine Herbs
- Marine Algae
- Marine Sponges
- Marine Fungi
- Marine Bacteria
- Marine Coral Reefs
- Marine Carrageenan Polysaccharides
- Marine Seaweeds
- Marine Ascidiaceans
- Marine Diatoms
- Marine Actinomycetes
- Marine-Derived Drugs in Clinical Trials
- CONCLUSION
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEDGEMENTS
- REFERENCES
- PDX Clinical Trial Design in Anti-Cancer Research
- Samad Muhammadnejad1,2,┼, Seyed Mostafa Monzavi1,3,4,┼, Amir Arsalan Khorsand1,2 and Abdol-Mohammad Kajbafzadeh2,4,*
- INTRODUCTION
- RATIONALE FOR PRECLINICAL PDX-BASED STUDIES
- METHODS FOR DEVELOPMENT OF PDX MODELS
- Choice of Proper Animal for PDX Development
- Single-Gene Mutation Mouse Strains
- Multi-Gene Mutation Mouse Strains
- General Procedure of PDX Development
- Step I: Tissue Procurement and Shipping
- Step II: Tissue Preparation (Processing)
- Step III: Tumor Implantation
- Breast Cancer
- Lung Cancer
- Liver Tumors
- Pancreatic Cancer
- Colon Cancer
- Ovarian Cancer
- Cervical Cancer
- Renal Tumors
- Prostate Cancer
- Melanoma
- Brain Tumors
- Hints on Some PDX Models
- CHARACTERIZATION AND VALIDATION OF PDX MODELS
- Clinicodemographic Features of the Submitter Patient
- Histopathologic Background of the Primary Tumor
- Quality Assurance of the PDX Tumor
- Pathogen Contamination Assessments
- Propagability or Tumor Regrowth Profile
- Establishment of a Well-Characterized PDX Biorepository/Biobank
- PDX-BASED TRIAL DESIGN
- Methodologic Considerations of PDX Clinical Trials
- Sample Size Estimation
- Model Establishment
- Treatment plan
- Staging Day
- Route of Administration
- Treatment Dose
- Dosing Interval
- Treatment Duration
- Outcome Measures
- Ethical Considerations
- LIMITATIONS OF PDX-BASED STUDIES
- CONCLUSION
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEDGEMENTS
- REFERENCES
- Subject Index
- Back Cover
